North American Poisonous Bites and Stings

Critical Care Clinics

Volumn 28, Issue 4, 2012, Pages 633-659

  Quan, Dan ^a,b  

^a MARICOPA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Envenomations; North America; Poisonous bites; Poisonous stings

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; ANTISERUM; BENZODIAZEPINE; CORTICOSTEROID; SNAKE VENOM ANTISERUM; VENOM ANTISERUM; VIPER VENOM;

ARACHNID; BEE STING; BITES AND STINGS; ENVENOMATION; HEALTH CARE FACILITY; HUMAN; HYMENOPTERA; INTENSIVE CARE; LATRODECTUS SPECIES; LOXOSCELES RECLUSA; NONHUMAN; POISONOUS SCORPION; PRIORITY JOURNAL; REVIEW; SCORPION; SNAKE; SNAKEBITE; SPIDER; SPIDER BITE; TOXIC ORGANISM; WASP;

AGKISTRODON; ANIMALS; ANTIVENINS; ARACHNIDISM; CRITICAL CARE; CROTALUS; ELAPIDAE; HUMANS; HYMENOPTERA; INSECT BITES AND STINGS; NORTH AMERICA; SCORPIONS; SNAKE BITES; SPIDERS;

EID: 84866502198     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2012.07.010     Document Type: Review

References (111)

1. Goddard J. Physician's guide to arthropods of medical importance 2000, CRC Press, Boca Raton (FL), p. 1-396. 3rd edition.
2. Mebs D. Venomous and poisonous animals 2002, CRC Press, Boca Raton (FL).
3. Steen C.J., Carbonaro P.A., Schwartz R.A. Arthropods in dermatology. J Am Acad Dermatol 2004, 50(6):819-842.
4. Stafford C.T. Hypersensitivity to fire ant venom. Ann Allergy Asthma Immunol 1996, 77(2):87-95.
5. Sherman R.A. What physicians should know about Africanized honeybees. West J Med 1995, 163(6):541-546.
6. Taber S. Fire Ants 2000, Texas A&M University Press, College Station (TX).
7. Kemp S.F., de Shazo R.D., Mofitt J.E., et al. Expanding habitat of the imported fire ant (Solenopsis invicta): a public health concern. J Allergy Clin Immunol 2000, 105(4):683-691.
8. Klotz J.H., Pinnas J.L., Greenberg L., et al. What's eating you? Native and imported fire ants. Cutis 2009, 83(1):17-20.
9. Conniff R. Stung: How tiny little insects get us to do exactly as they wish. Discover 2003, 6:67.
10. Blaser K., Carballido J., Faith A., et al. Determinants and mechanisms of human immune responses to bee venom phospholipase A2. Int Arch Allergy Immunol 1998, 117(1):1-10.
11. Lichtenstein L.M., Valentine M.D., Sobotka A.K. Insect allergy: the state of the art. J Allergy Clin Immunol 1979, 64(1):5-12.
12. Petroianu G., Liu J., Helfrich U., et al. Phospholipase A2-induced coagulation abnormalities after bee sting. Am J Emerg Med 2000, 18(1):22-27.
13. Muller U.R. Hymenoptera venom proteins and peptides for diagnosis and treatment of venom allergic patients. Inflamm Allergy Drug Targets 2011, 10(5):420-428.
14. Van der Linden P.W., Struyvenberg A., Kraaijenhagen R.J., et al. Anaphylactic shock after insect-sting challenge in 138 persons with a previous insect-sting reaction. Arch Intern Med 1993, 118(3):161-168.
15. Reisman R.E. Natural history of insect sting allergy: relationship of severity of symptoms of initial anaphylaxis to re-sting reactions. J Allergy Clin Immunol 1992, 90(3 Pt 1):335-339.
16. Erickson T.B., Marquez A. Arthropod envenomation and parasitism. Wilderness medicine 2007, Mosby, Philadelphia, p. 1051-85. 5th edition.
17. Meier J. Biology and distribution of hymenopterans of medical importance, their venom apparatus and venom composition. Handbook of clinical toxicology of animal venoms and poisons 1995, 331-348. CRC Press, Boca Raton (FL). J. Meier, J. White (Eds.).
18. Schmidt J.O. Allergy to venomous insects. The hive and the honeybee 1992, 1209-1269. Dadant & Sons, Hamilton (IL). J.M. Graham (Ed.).
19. Visscher P.K., Vetter R.S., Camazine S. Removing bee stings. Lancet 1996, 348(9023):301-302.
20. Available at: Accessed April 2, 2012. http://spiders.ucr.edu/images/colorloxmap.gif.
21. Chavez-Olortegui C., Zanetti V.C., Ferreira A.P., et al. ELISA for the detection of venom antigens in experimental and clinical envenoming by loxosceles intermedia spiders. Toxicon 1998, 36(4):563-569.
22. Futrell J.M. Loxoscelism. Am J Med Sci 1992, 304(4):261-267.
23. Yarbrough B. Current treatment of brown recluse spiders. Curr Concepts Wound Care 1987, 10(4):4-6.
24. Rees R., Campbell D., Rieger E., et al. The diagnosis and treatment of brown recluse spider bites. Ann Emerg Med 1987, 16(9):945-949.
25. Gendron B.P. Loxosceles reclusa envenomation. Am J Emerg Med 1990, 8(1):51-54.
26. Vorse H., Seccareccio P., Woodruff K., et al. Disseminated intravascular coagulopathy following fatal brown spider bite (necrotic arachnidism). J Pediatr 1972, 80(6):1035-1037.
27. Bernstein B., Ehrlich F. Brown recluse spider bites. J Emerg Med 1986, 4(6):457-462.
28. Cacy J., Mold J.W. The clinical characteristics of brown recluse spider bites treated by family physicians: an OKPRN Study. Oklahoma Physicians Research Network. J Fam Pract 1999, 48(7):536-542.
29. Franca F.O., Barbaro K.C., Abdulkader R.C. Rhabdomyolysis in presumed viscero-cutaneous loxoscelism: report of two cases. Trans R Soc Trop Med Hyg 2002, 96(3):287-290.
30. Isbister G.K., Fan H.W. Spider bite. Lancet 2011, 378(9808):2039-2047.
31. King L.E., Rees R.S. Dapsone treatment of a brown recluse bite. JAMA 1987, 250(5):648.
32. Hobbs G.D., Anderson A.R., Greene T.J., et al. Comparison of hyperbaric oxygen and dapsone therapy for loxosceles envenomation. Acad Emerg Med 1996, 3(8):758-761.
33. Phillips S., Kohn M., Baker D., et al. Therapy of brown spider envenomation: a controlled trial of hyperbaric oxygen, dapsone, and cyproheptadine. Ann Emerg Med 1995, 25(3):363-368.
34. Rees R.S., Altenbern D.P., Lynch J.B., et al. Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision. Ann Surg 1985, 202(5):659-663.
35. Svendsen F.J. Treatment of clinically diagnosed brown recluse spider bites with hyperbaric oxygen: a clinical observation. J Ark Med Soc 1986, 83(5):199-204.
36. Maynor M.L., Moon R.E., Klitzman B., et al. Brown recluse spider envenomation: a prospective trial of hyperbaric oxygen therapy. Acad Emerg Med 1997, 4(3):184-192.
37. Hobbs G.D. Brown recluse spider envenomation: is hyperbaric oxygen the answer?. Acad Emerg Med 1997, 4(3):165-166.
38. Geppert M., Khvotchev M., Krasnoperov V., et al. Neurexin I alpha is a major alpha-latrotoxin receptor that cooperates in alpha-latrotoxin action. J Biol Chem 1998, 273(3):1705-1710.
39. van Renterghem C., Iborra C., Martin-Moutot N., et al. α-Latrotoxin forms calcium-permeable membrane pores via interactions with latrophilin or neurexin. Eur J Neurosci 2000, 12(11):3953-3962.
40. Clark R.F. The safety and efficacy of antivenin Latrodectus mactans. J Toxicol Clin Toxicol 2001, 39(2):125-127.
41. Clark R.F., Wethern-Kestner S., Vance M.V., et al. Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases. Ann Emerg Med 1992, 21(7):782-787.
42. Maretic Z. Latrodectism: variations in clinical manifestations provoked by latrodectus species of spiders. Toxicon 1983, 21(4):457-466.
43. Sutherland S.K., Trinca J.C. Survey of 2144 cases of redback spider bites. Med J Aust 1978, 2(14):620-623.
44. Hoover N.G., Fortenberry J.D. Use of antivenin to treat priapism after a black widow spider bite. Pediatrics 2004, 114(1):e128-e129.
45. Quan D., Ruha A.M. Priapism associated with latrodectus mactans envenomation. Am J Emerg Med 2009, 27(6):759.e1-759.e2.
46. Russell F.E., Marcus P., Streng J.A. Black widow spider envenomation during pregnancy. Report of a case. Toxicon 1979, 17(2):188-189.
47. Wolfe M.D., Meyers O., Carvati E.M., et al. Black widow spider envenomation in pregnancy. J Matern Fetal Neonatal Med 2011, 24(1):122-126.
48. Sherman R.P., Groll J.M., Gonzalez D.I., et al. Black widow spider (Latrodectus mactans) envenomation in a term pregnancy. Curr Surg 2000, 57(4):346-348.
49. Handel C.C., Izquierdo L.A., Curet L.B. Black widow spider (Latrodectus mactans) bite during pregnancy. West J Med 1994, 160(3):261-262.
50. Antivenin (latrodectus mactans), black widow spider antivenin, equine origin 2005, [Package insert], Merck & Co, Whitehouse Station (NJ).
51. Heard K., O'Malley G.F., Dart R.C. Antivenom therapy in the Americas. Drugs 1999, 58(1):5-15.
52. Murphy C.M., Hong J.J., Beuhler M.C. Anaphylaxis with latrodectus antivenin resulting in cardiac arrest. J Med Toxicol 2011, 7(4):317-321.
53. Offerman S.R., Daubert G.P., Clark R.F. The treatment of black widow spider envenomation with Lactrodectus mactans: a case series. Permanente J 2011, 15(3):76-81.
54. Available at: Accessed January 15, 2012. http://www.upi.com/Odd_News/2009/07/20/Scorpions-on-a-plane/UPI-25831248119511/.
55. Available at: Accessed January 15, 2012. http://abcnews.go.com/US/scorpion-stings-man-flight-seattle-anchorage/story%3Fid=13969984#.T00g3chXNY8.
56. Stachel S.J., Stockwell S.A., van Vranken D.L. The fluorescence of scorpions and cataractogenesis. Chem Biol 1999, 6(8):531-539.
57. Bartholomew C. Acute scorpion pancreatitis in Trinidad. BMJ 1970, 1(5967):666-668.
58. LoVecchio F., McBride C. Scorpion envenomation in young children in central Arizona. Clin Toxicol 2003, 41(7):937-940.
59. Chase P., Boyer-Hassen L., McNally J., et al. Serum levels and urine detection of Centruroides sculpturatus venom in significantly envenomated patients. Clin Toxicol 2009, 47(1):24-28.
60. Curry S.C., Vance M.V., Ryan P.J., et al. Envenomation by the scorpion Centruroides sculpturatus. J Toxicol Clin Toxicol 1983-1984, 21(4-5):417-449.
61. Bronstein A.C., Spyker D.A., Cantilena L.R., et al. 2010 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th annual report. Clin Toxicol 2011, 49(10):910-941.
62. Anascorp® centruroides (scorpion) immune F(ab')2 (equine) injection 2011, [Package insert], Rare Disease Therapeutics, Franklin (TN).
63. Boyer L.V., Theodorou A.A., Berg R.A., et al. Antivenom for critically ill children with neurotoxicity from scorpion stings. N Engl J Med 2009, 360(20):2090-2098.
64. Riley B.D., LoVecchio F., Pizon A.F. Lack of scorpion antivenom leads to increased pediatric ICU admissions. Ann Emerg Med 2006, 47(4):398-399.
65. Holstege C.P., Miller M.B., Wermuth M., et al. Crotalid snake envenomation. Crit Care Clin 1997, 13(4):889-921.
66. Alape-Giron A., Stiles B., Schmidt J., et al. Characterization of multiple nicotinic acetylcholine receptor-binding proteins and phospholipases A2 from the venom of the coral snake Micrurus nigrocinctus. FEBS Lett 1996, 380(1-2):29-32.
67. Rosso J.P., Vargas-Rosso O., Gutierrez J.M., et al. Characterization of alpha-neurotoxin and phospholipase A2 activities from Micrurus venoms. Determination of the amino acid sequence and receptor binding ability of the major alpha-neurotoxin from Micrurus nigrocinctus nigrocinctus. Eur J Biochem 1996, 238(1):231-239.
68. Ramsey G.F., Klickstein G.D. Coral snake bite: report of a case and suggested therapy. JAMA 1962, 182(9):949-951.
69. Kitchens C.S., Van Mierop L.H. Envenomation by the Eastern coral snake (Micrurus fulvius fulvius): a study of 39 victims. JAMA 1987, 258(12):1615-1618.
70. Moseley T. Coral snake bite: recovery following symptoms of respiratory paralysis. Ann Surg 1966, 163(6):943-948.
71. Morgan D.L., Borys D.J., Stanford R., et al. Texas coral snake (Micrurus tener) bites. South Med J 2007, 100(2):152-156.
72. Russell F.E. Snake venom poisoning 1983, Scholium International, Great Neck (NY), p. 281. 2nd edition.
73. Wingert W.A., Wainschel J. Diagnosis and management of envenomation by poisonous snakes. South Med J 1975, 68(8):1015-1026.
74. Jansen P.W., Perkin R.M., VanStralen D. Mojave rattlesnake envenomation: prolonged neurotoxicity and rhabdomyolysis. Ann Emerg Med 1992, 21(3):322-325.
75. Walter F.G., Chase P.B., Fernandez M.C., et al. Venomous snakes. Haddad and winchester's clinical management of poisoning and drug overdose 2007, 399-422. Saunders Elsevier, Philadelphia. 4th edition. M.W. Shannon, S.W. Borron, M. Burns (Eds.).
76. Carroll R.R., Hall E.L., Kitchens C.S. Canebrake rattlesnake envenomation. Ann Emerg Med 1997, 30(1):45-48.
77. Walker J.P., Morrison R.L. Current management of copperhead snakebite. J Am Coll Surg 2011, 212(14):470-475.
78. Russell F.E., Carlson R.W., Wainschel J., et al. Snake venom poisoning in the United States experience with 550 cases. JAMA 1975, 233(4):341-344.
79. Boyer L.V., Seifert S.A., Clark R.F., et al. Recurrent and persistent coagulopathy following pit viper envenomation. Arch Intern Med 1999, 159(7):706-710.
80. Guisto J.A. Severe toxicity from crotalid envenomation after early resolution of symptoms. Ann Emerg Med 1995, 26(3):387-389.
81. Swindel G.M., Seaman K.G., Arthur D.C., et al. The six hour observation rule for grade I crotalid envenomation: is it sufficient?. J Wilderness Med 1992, 3(2):168-172.
82. Balestrieri F., Fisher S. Analgesics. The pharmacologic approach to the critically ill patient 1994, 640-650. Williams & Wilkins, Baltimore (MD). 3rd edition. B. Chernow (Ed.).
83. LoVecchio F., Klemens J., Welch S., et al. Antibiotics after rattlesnake envenomation. J Emerg Med 2002, 23(4):327-328.
84. Clark R.F., Selden B.S., Furbee B. The incidence of wound infection following crotalid envenomation. J Emerg Med 1993, 11(5):583-586.
85. Vomero V.U., Marques M.J., Neto H.S. Treatment with an anti-inflammatory drug is detrimental for muscle regeneration at Bothrops jararacussu envenoming: an experimental study. Toxicon 2009, 54(3):361-363.
86. Nuchprayoon I., Pongpan C., Sripaiboonkij N. The role of prednisolone in reducing limb oedema in children bitten by green pit vipers: a randomized, controlled trial. Ann Trop Med Parasitol 2008, 102(7):643-649.
87. CroFab® (crotalidae) polyvalent immune fab (ovine) 2011, [Package insert], Protherics, Brentwood (TN).
88. Norris R.L., Bush S.P. Bites by venomous reptiles in the Americas. Wilderness medicine 2007, 1051-1085. Mosby, Philadelphia. 5th edition. P.S. Auerbach (Ed.).
89. American College of Medical Toxicology, American Academy of Clinical Toxicology, American Association of Poison Control Centers, et al. Pressure immobilization after North American crotalinae snake envenomation. Clin Toxicol 2011, 49(10):881-882.
90. Trevett A.J., Nwokolo N., Watters D.A., et al. Tourniquet injury in a Papuan snakebite victim. Trop Geogr Med 1993, 45(6):305-307.
91. Curry S., Kraner J., Kunkel D. Noninvasive vascular studies in management of rattlesnake envenomations to extremities. Ann Emerg Med 1985, 14(11):1081-1084.
92. Tanen D., Ruha A., Graeme K., et al. Epidemiology and hospital course of rattlesnake envenomations cared for at a tertiary referral center in Central Arizona. Acad Emerg Med 2001, 8(2):177-182.
93. Smith T.A., Figge H.L. Treatment of snakebite poisoning. Am J Hosp Pharm 1991, 48(10):2190-2196.
94. Tokish J.T., Benjamin J., Walter F. Crotalid envenomation: the southern Arizona experience. J Orthop Trauma 2001, 15(1):5-9.
95. Dart R.C. Can steel heal a compartment syndrome caused by rattlesnake venom?. Ann Emerg Med 2004, 44(2):105-107.
96. Cumpston K.L. Is there a role for fasciotomy in crotalinae envenomations in North America?. Clin Toxicol 2011, 49(5):351-365.
97. Hardy D.L., Zamudio K.R. Compartment syndrome, fasciotomy, and neuropathy after a rattlesnake envenomation: aspects of monitoring and diagnosis. Wilderness Environ Med 2006, 17(1):36-40.
98. Gutierrez J.M., Leon G., Lomonte B., et al. Antivenoms for snakebite envenomings. Inflamm Allergy Drug Targets 2011, 10(5):369-380.
99. Ruha A.M., Curry S.C., Albrecht C., et al. Late hematologic toxicity following treatment of rattlesnake envenomation with crotalidae polyvalent immune Fab antivenom. Toxicon 2011, 57(1):53-59.
100. Seifert S.A., I Kirschner R., Martin N. Recurrent, persistent, or late, new-onset hematologic abnormalities in crotaline snakebite. Clin Toxicol 2011, 49(4):324-329.
101. Boyer L.V., Seifert S.A., Cain J.S. Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 2. guidelines for clinical management with crotaline Fab antivenom. Ann Emerg Med 2001, 37(2):196-201.
102. Antivenin (micrurus fulvius), (equine origin). North American coral snake antivenin 2001, [Package insert], Wyeth Laboratories, Marietta (GA).
103. Corrigan P., Russell F.E., Wainschel J. Clinical reactions to antivenin. Toxins: animal, plant and microbial 1978, 457-465. Pergamon Press, New York. P. Rosenberg (Ed.).
104. LoVecchio F., Klemens J., Roundy E.B., et al. Serum sickness following administration of antivenin (Crotalidae) polyvalent in 181 cases of presumed rattlesnake envenomation. Wilderness Environ Med 2003, 14(4):200-221.
105. Warrell D.A. WHO/SEARO guidelines for the clinical management of snake bites in Southeast Asian region. Southeast Asian J Trop Med Public Health 1999, 30(Suppl 1):1-85.
106. Jurkovich G.J., Luterman A., McCullar K., et al. Complications of crotalidae antivenin therapy. J Trauma 1988, 28(7):1032-1037.
107. Cupo P., Azevedo-Marques M.M., de Menezes J.B., et al. Immediate hypersensitivity reactions after intravenous use of antivenin sera: prognostic value of intradermal sensitivity tests. Rev Inst Med Trop Sao Paulo 1991, 33(2):115-122.
108. Thiansookon A., Rojnuckarin P. Low incidence of early reactions to horse-derived F(ab')2 antivenom for snakebites in Thailand. Acta Trop 2008, 105(2):203-205.
109. LaMonica G.E., Seifert S.A., Rayburn W.F. Rattlesnake bites in pregnant women. J Reprod Med 2010, 55(11-12):520-522.
110. Pizon A.F., Riley B.D., LoVecchio F., et al. Safety and efficacy of crotalidae polyvalent immune Fab in pediatric crotaline envenomations. Acad Emerg Med 2007, 14(4):373-376.
111. Offerman S.R., Bush S.P., Moynihan J.A., et al. Crotaline Fab antivenom for the treatment of children with rattlesnake envenomation. Pediatrics 2002, 110(5):968-971.